WebDoctor Encyclopedia

Head & neck

Myoepithelial carcinoma of the salivary gland

Myoepithelial carcinoma is a rare salivary gland cancer built from the contractile cells around the saliva ducts. It usually forms a painless lump in the parotid of an older adult, may arise in a benign mixed tumour, and is treated with surgery and often radiotherapy.

Medically reviewed Last reviewed October 20, 2026

What is myoepithelial carcinoma of the salivary gland?

Myoepithelial carcinoma is a rare salivary gland cancer. It is also known as malignant myoepithelioma.

Salivary glands contain two main kinds of lining cell. Ductal cells line the small tubes that carry saliva. Myoepithelial cells wrap around these tubes and squeeze to push saliva out. In myoepithelial carcinoma, the cancer cells look and behave almost entirely like myoepithelial cells.

The tumour usually appears as a slow-growing, painless lump, most often in the parotid gland in front of the ear (Vilar-Gonzalez et al., 2015). It mostly affects adults over 50, and men and women are affected in similar numbers (Lavareze et al., 2023).

About half of myoepithelial carcinomas develop inside a long-standing benign pleomorphic adenoma (a benign mixed tumour). The rest arise de novo, without an earlier lump. In the past many of these cancers were labelled “malignant mixed tumour”, so the disease was probably under-recognised (Savera et al., 2000).

Behaviour varies widely. Some tumours stay local for years, while others come back after surgery or spread to the lungs. Treatment is mainly surgery with clear margins, often followed by radiotherapy.

1. Key facts at a glance

Feature Details
Type of cancer Salivary gland carcinoma made almost entirely of myoepithelial cells
Also called Malignant myoepithelioma
How common Rare; a small percentage of salivary gland cancers
Typical age Mostly over 50; mean in the mid-50s
Sex Men and women affected about equally
Main site Parotid gland (about half); also submandibular and minor salivary glands
Origin Within a pleomorphic adenoma, or de novo
Main treatment Surgery, often with radiotherapy
Outlook Variable; roughly half alive at 5 years in pooled reports

2. Types of myoepithelial carcinoma

By origin

Type Description
De novo Arises without a known earlier tumour
Myoepithelial carcinoma ex pleomorphic adenoma Develops within a benign mixed tumour; a common form
Arising from a benign myoepithelioma Less common

By cell type

The cancer cells can take on several shapes, and many tumours contain a mixture.

Cell type Appearance Notes
Epithelioid Rounded or polygonal cells Common
Clear Pale, glycogen-rich cytoplasm Seen in about 4 in 10 cases
Spindle Long, slender cells Can mimic a sarcoma
Plasmacytoid (hyaline) Cells with an off-centre nucleus and glassy cytoplasm Linked to shorter disease-free survival
Mixed Combination of the above Frequent

In a systematic review of 71 patients, plasmacytoid cells and a solid growth pattern were associated with earlier recurrence (Lavareze et al., 2023).

By grade

Tumours may be low grade or high grade under the microscope. High-grade tumours are more likely to spread.

Tumour Key difference
Benign myoepithelioma Same cells but no invasion of surrounding tissue
Pleomorphic adenoma Benign; contains both ductal and myoepithelial cells with cartilage-like stroma
Epithelial-myoepithelial carcinoma Two-layer structure of ductal and myoepithelial cells
Carcinoma ex pleomorphic adenoma (other types) The cancerous part is not myoepithelial, for example salivary duct carcinoma
Adenoid cystic carcinoma Has a typical sieve-like pattern and MYB gene changes

The salivary glands

Gland Position Share of myoepithelial carcinomas
Parotid In front of and below the ear The largest share, about half
Submandibular Under the jaw Less common
Sublingual Under the tongue Rare
Minor salivary glands Hundreds of tiny glands in the palate, cheeks, lips, throat and nose A notable minority, especially the palate

The facial nerve, which controls the muscles of facial expression, runs through the parotid gland. This is why parotid tumours and their treatment can affect facial movement.

3. Causes and risk factors

The exact cause is unknown.

Factor Notes
Long-standing pleomorphic adenoma Especially one present for many years or that has recurred
Age over 50 Most patients are older adults
Previous radiotherapy to the head and neck Increases the risk of salivary gland cancers generally
Gene changes Some tumours carry PLAG1 or HMGA2 changes (from a mixed tumour) or EWSR1 fusions

Myoepithelial carcinoma is not inherited, and no lifestyle factor has been clearly linked to it.

4. How does it look

From the outside

Feature Description
Lump Firm swelling in front of or below the ear, under the jaw, or in the mouth
Growth Slow at first; may speed up
Skin Usually normal; may become fixed or red in advanced cases
Face Weakness on one side if the facial nerve is involved

On scans

Ultrasound, MRI and CT show a lump that may look well defined or irregular. MRI is useful for showing whether the tumour has spread along nerves or into the deep part of the parotid.

Under the microscope

Feature Description
Growth pattern Multiple nodules, often with a crowded rim of cells and a central area of dead or myxoid tissue
Cells Epithelioid, clear, spindle or plasmacytoid
Background Myxoid (jelly-like) or hyalinised (glassy) material
Invasion Infiltrates surrounding tissue; may involve nerves
Stains Positive for cytokeratins, S100 and vimentin; often SOX10, calponin, p63 and smooth muscle actin

In the series of 25 patients reported by Savera and colleagues, all tumours grew in an infiltrative way, and most had the typical multinodular pattern (Savera et al., 2000).

5. Symptoms

Common symptoms

  • A painless lump in front of or below the ear
  • A lump under the jaw
  • A swelling in the mouth or palate (for minor salivary glands)
  • Change in an old lump, such as sudden growth

Less common symptoms

Symptom What it may mean
Pain Nerve involvement or rapid growth
Facial weakness or drooping Involvement of the facial nerve
Numbness Nerve involvement
Lumps in the neck Possible lymph node spread
Cough or breathlessness Possible lung spread

Because these cancers are often painless, people may wait months or even years before seeing a doctor (Vilar-Gonzalez et al., 2015).

When to seek medical advice

See a doctor about any lump near the ear, under the jaw or in the mouth that lasts more than three weeks, and especially if an old lump starts to grow, becomes painful, or if you notice facial weakness.

6. Diagnosis

Test Purpose
Ultrasound First scan for a salivary gland lump
Fine needle aspiration or core biopsy Samples the lump; diagnosis may be difficult on a small sample
MRI Shows local extent and nerve involvement
CT of the neck and chest Checks lymph nodes and lungs
PET-CT In selected high-grade tumours
Final pathology after surgery Often needed to confirm the diagnosis

Needle samples can be hard to interpret, because the cells may look bland and the background material can resemble a benign mixed tumour (Argyris and Wakely, 2023).

Staging

Myoepithelial carcinoma of a major salivary gland is staged with the TNM system for salivary gland cancers. It takes into account tumour size, spread beyond the gland, lymph nodes and distant spread.

7. Treatment

Treatment is planned by a head and neck cancer team.

Surgery

Situation Usual operation
Tumour in the outer parotid Superficial or partial parotidectomy
Tumour in the deep parotid or larger tumour Total parotidectomy, keeping the facial nerve if possible
Submandibular gland Removal of the gland
Minor salivary gland Wide local excision, sometimes with bone removal
Lymph node spread Neck dissection
High-grade tumour Neck dissection may be offered even if nodes look normal

The facial nerve is preserved unless the cancer is growing into it.

Radiotherapy

Situation Role
Close or positive margins Lowers the risk of local recurrence
High-grade tumour Often advised
Nerve or vessel invasion Often advised
Lymph node spread Treats the neck

In pooled data, patients treated with more than one type of treatment, such as surgery plus radiotherapy, had longer disease-free survival (Lavareze et al., 2023).

Drug treatment

There is no standard chemotherapy. For spread to other organs, doctors may use platinum-based chemotherapy, or targeted drugs if testing finds a suitable change. Clinical trials should be considered.

Side effects

Treatment Possible side effects
Parotid surgery Temporary facial weakness, numbness of the earlobe, sweating while eating (Frey syndrome)
Neck dissection Shoulder stiffness, neck numbness
Radiotherapy Dry mouth, sore skin, taste changes, hearing changes

What treatment involves day to day

Stage What to expect
Surgery 1-3 nights in hospital, with a drain for a day or two
Recovery Several weeks; facial weakness, if any, often improves over months
Radiotherapy Weekday sessions for around 6 weeks
After radiotherapy Dental care and mouth care are important

8. Outlook (prognosis)

The outlook ranges from long-term cure to aggressive disease.

Measure Reported results
2-year overall survival About two-thirds (Lavareze et al., 2023)
5-year overall survival Just under half in pooled data (Lavareze et al., 2023)
Recurrence Common, often more than once
Metastasis Mainly to the lungs; more often with high-grade tumours

In the Savera series, nearly half of the patients with follow-up developed metastases, and most of those had high-grade tumours (Savera et al., 2000).

Factor Effect
High grade Poorer outlook
Plasmacytoid cells or solid pattern Shorter time to recurrence
Clear surgical margins Better local control
Combined treatment Longer disease-free survival

Why recurrence happens

Myoepithelial carcinoma often grows as several nodules with an infiltrative edge. Small extensions of tumour may reach beyond the main lump, and some tumours follow nerves. If any of these are left behind, the cancer can regrow, sometimes more than once. This is why surgeons aim for a margin of normal tissue and why radiotherapy is frequently added.

9. Follow-up

Follow-up Purpose
Clinic visits every 2-3 months in year 1 Examination of the surgical site and neck
Then every 3-6 months up to year 5 Less frequent visits over time
MRI of the head and neck Looks for local recurrence
Chest CT Looks for lung spread, especially with high-grade tumours
Long-term follow-up Recurrence can occur late

10. Living with myoepithelial carcinoma

  • Do facial exercises if a physiotherapist recommends them for facial weakness
  • Protect your eye with drops and a shield at night if you cannot close it fully
  • Keep up dental checks after radiotherapy and use fluoride as advised
  • Sip water often and use saliva substitutes if your mouth is dry
  • Report new lumps, pain or a cough between appointments
  • Stop smoking, which slows healing and worsens radiotherapy side effects
  • Seek support from head and neck cancer groups

11. Frequently asked questions

Question Answer
Is it the same as a benign myoepithelioma? No; the carcinoma invades surrounding tissue and can spread
Did my old lump turn into cancer? That happens in a proportion of cases; others arise without an earlier lump
Will I lose movement in my face? Surgeons try hard to save the facial nerve; weakness is often temporary
Will I need radiotherapy? Often, especially for high-grade tumours or close margins
Can it spread? Yes, most often to the lungs
Is it inherited? No
Why was it hard to diagnose? The cells can look bland and resemble benign tumours on needle samples
Will I need chemotherapy? Not usually; it is reserved for cancer that has spread
How long is follow-up? Usually at least 5 years, and often longer

12. Questions to ask your care team

  • Did my cancer arise in a pleomorphic adenoma or de novo?
  • Is it low grade or high grade?
  • Were the margins clear?
  • Is my facial nerve at risk?
  • Do I need radiotherapy or neck surgery?
  • How often will I need scans of the chest?
  • Would genetic testing of the tumour change my treatment?

Resources

  1. Argyris, P.P. and Wakely, P.E. Jr (2023) ‘Cytopathology of salivary gland myoepithelial carcinoma: a study of 13 cases and review of the literature’, Journal of the American Society of Cytopathology, 12(6), pp. 461-468.
  2. Lavareze, L. et al. (2023) ‘Clinicopathological and survival profile of patients with salivary gland myoepithelial carcinoma: a systematic review’, Journal of Oral Pathology and Medicine, 52(2), pp. 101-108.
  3. Savera, A.T. et al. (2000) ‘Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients’, American Journal of Surgical Pathology, 24(6), pp. 761-774.
  4. Vilar-Gonzalez, S. et al. (2015) ‘Salivary gland myoepithelial carcinoma’, Clinical and Translational Oncology, 17(11), pp. 847-855.
  5. National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.